PODD

NEUTRAL

$201.47 Live

Insulet Corporation · NASDAQ

Target $333.3 (+65.4%)

$194.61 52W Range $354.88

PODD Insulet Corporation - Fundamental Analysis

NEUTRAL

Console Chart News

PODD Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$201.47

Analyst Target

$333.3

+65.4% Upside

52W High

$354.88

52W Low

$194.61

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026

Market cap

$14.18B

P/E

57.73

ROE

18.1%

Profit margin

9.1%

Debt/Equity

0.66

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

Insulet Corporation (PODD) presents a dichotomy between strong operational growth and a severely disconnected valuation. While the Piotroski F-Score of 4/9 indicates stable financial health and revenue growth is robust at 31.2%, the stock trades at a massive premium to its Graham Number ($41.11) and Intrinsic Value ($44.85). Despite a 'strong_buy' analyst consensus and a high target price of $333.30, the technical trend is aggressively bearish with a 36.3% decline over the last six months. The investment case relies entirely on future growth scaling and the successful international rollout of Omnipod 5 to justify the current P/E of 57.73.

Key Strengths

Exceptional gross margins (71.63%) indicating strong pricing power and product value

Robust top-line growth with 31.2% YoY revenue increase

Strong liquidity position with a current ratio of 2.81

Consistent history of earnings beats (3/4 most recent quarters)

Successful expansion of Omnipod 5 into multiple international markets

Key Risks

Extreme valuation premium relative to defensive fair value (Graham Number)

Severe bearish technical momentum (0/100 trend score)

Earnings growth (3.9% YoY) is significantly lagging behind revenue growth

Dependence on third-party CGM integrations (Dexcom, Abbott)

Bearish insider sentiment with recent selling activity

AI Fair Value Estimate

Based on comprehensive analysis

$142.5

-29.3% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Growth-Dependent Speculation

Key drivers: Omnipod 5 adoption, International market penetration, Valuation compression

Confidence

80%

Value

20/100

Ref P/E 57.73, PEG 1.12, Graham Number $41.11

Positives

Forward P/E (24.93) is significantly lower than trailing P/E

Watchpoints

Price ($201.47) is ~4.9x the Graham Number
Price/Book ratio is very high at 9.36

Future

85/100

Ref Growth rates and 10-K expansion plans

Positives

31.2% Revenue growth
Strong analyst target price of $333.30
Expansion into 9 additional countries in 2025

Watchpoints

Slow conversion of revenue growth to bottom-line earnings growth

Past

60/100

Ref Historical trends and Earnings track record

Positives

Consistent earnings surprises (Avg 13.62% last 4 quarters)

Watchpoints

Poor multi-year price performance (5Y Change: -28.4%)

Health

65/100

Ref Piotroski F-Score 4/9

Positives

Low Debt/Equity (0.66)
Strong Current Ratio (2.81)

Watchpoints

Piotroski F-Score of 4/9 is only 'Stable', not 'Strong'

Dividend

0/100

Ref Yield N/A

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$201.47

Analyst Target

$333.3

Upside/Downside

+65.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PODD and closest competitors.

Updated 2026-04-16

Company	5Y	3Y	1Y	6M	1M	1W
PODD Insulet Corporation Primary	-28.4%	-37.3%	-19.6%	-36.3%	-12.6%	+1.0%
MEDP Medpace Holdings, Inc. Peer	+181.9%	+160.9%	+64.2%	-5.0%	+11.3%	+1.1%
ASND Ascendis Pharma A/S Peer	+53.7%	+106.6%	+48.4%	+15.5%	+2.0%	-6.1%
BBIO BridgeBio Pharma, Inc. Peer	+18.4%	+720.5%	+110.0%	+68.2%	+1.8%	+2.1%
NBIX Neurocrine Biosciences, Inc. Peer	+34.2%	+30.1%	+19.1%	-6.2%	-0.5%	+3.0%

POD

Insulet Corporation

Primary

-28.4%

-37.3%

-19.6%

-36.3%

-12.6%

+1.0%

MED

Medpace Holdings, Inc.

Peer

+181.9%

+160.9%

+64.2%

-5.0%

+11.3%

+1.1%

ASN

Ascendis Pharma A/S

Peer

+53.7%

+106.6%

+48.4%

+15.5%

+2.0%

-6.1%

BBI

BridgeBio Pharma, Inc.

Peer

+18.4%

+720.5%

+110.0%

+68.2%

+1.8%

+2.1%

NBI

Neurocrine Biosciences, Inc.

Peer

+34.2%

+30.1%

+19.1%

-6.2%

-0.5%

+3.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

57.73

24.93

1.12

9.36

5.24

5.34

25.65

$14.18B

Profitability

Profit margins and return metrics

Profit Margin 9.12%

Operating Margin 18.67%

Gross Margin 71.63%

ROE 18.12%

ROA 9.43%

Growth

Revenue and earnings growth rates

Revenue Growth +31.2%

Earnings Growth +3.9%

Q/Q Revenue Growth +31.18%

Q/Q Earnings Growth +0.9%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.66

Moderate

Current Ratio

2.81

Strong

Quick Ratio

1.81

Excellent

Cash/Share

$10.17

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.8B

Gross Margin

72.5%

Op. Margin

18.7%

Net Margin

13.0%

Total Assets

$3.2B

Liabilities

$1.7B

Equity

$1.5B

Debt/Equity

1.11x

Operating CF

$0.2B

CapEx

$-0.1B

Free Cash Flow

$0.0B

FCF Yield

18%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06

$N/A

2026-02-18

$1.55

+6.0% surprise

2025-11-06

$1.24

+8.1% surprise

2025-08-07

$1.17

+26.8% surprise

Healthcare Sector Comparison

Comparing PODD against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)

P/E Ratio

57.73

This Stock

90.61

Sector Avg

-36.3% (Discount)

Return on Equity (ROE)

18.12%

This Stock

-101.52%

Sector Avg

-117.9% (Below Avg)

Profit Margin

9.12%

This Stock

-12.47%

Sector Avg

-173.2% (Weaker)

Debt to Equity

0.66

This Stock

3.4

Sector Avg

-80.5% (Less Debt)

Revenue Growth

31.2%

This Stock

124.21%

Sector Avg

-74.9% (Slower)

Current Ratio

2.81

This Stock

4.56

Sector Avg

-38.3% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PODD Insulet Corporation	NEUTRAL	$14.18B	57.73	18.1%	9.1%	$201.47
MEDP Medpace Holdings, Inc.	NEUTRAL	$14.31B	32.76	70.2%	17.8%	$501.23	Compare
ASND Ascendis Pharma A/S	BULLISH	$13.87B	-	-%	-31.7%	$225.98	Compare
BBIO BridgeBio Pharma, Inc.	BEARISH	$14.92B	-	-%	-225.3%	$77.87	Compare
NBIX Neurocrine Biosciences, Inc.	BULLISH	$13.22B	28.15	16.4%	16.7%	$131.74	Compare

PODD Insulet Corporation

NEUTRAL

Mkt Cap

$14.2B

P/E

57.7

ROE

18.1%

Price

$201.47

MEDP Medpace Holdings, Inc.

Compare with PODD

ASND Ascendis Pharma A/S

Compare with PODD

BBIO BridgeBio Pharma, Inc.

Compare with PODD

Compare with PODD

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-01	PANOS MICHAEL	Officer	Stock Award	2,777	-
2026-03-31	HUFFINES ROBERT LUTHER	Director	Stock Award	111	$23,292
2026-02-25	MINOGUE MICHAEL R	Director	Purchase	2,030	$499,847
2026-02-24	KAPPLES JOHN W.	General Counsel	Stock Award	1,885	-
2026-02-24	BENJAMIN ERIC	Chief Operating Officer	Stock Award	3,822	-
2026-02-24	MCEVOY ASHLEY	Chief Executive Officer	Stock Award	10,046	-
2026-02-24	BUDDEN LAUREN	Officer	Stock Award	611	-
2026-02-24	PEASE FLAVIA H.	Chief Financial Officer	Stock Award	3,822	-
2026-02-24	SINGH PREM	Officer	Stock Award	2,140	-
2026-02-24	COUSIN LAETITIA	Officer	Stock Award	1,044	-
2026-02-24	DAVIS LISA BLAIR	Officer	Stock Award	2,140	-
2026-02-12	KAPPLES JOHN W.	General Counsel	Stock Award	5,246	-
2026-02-12	BENJAMIN ERIC	Chief Operating Officer	Stock Award	7,236	-
2026-02-12	BUDDEN LAUREN	Officer	Stock Award	1,808	-
2026-02-12	SINGH PREM	Officer	Stock Award	2,532	-

PANOS MICHAEL

Officer

Stock Award

2026-04-01

2,777 shares

HUFFINES ROBERT LUTHER

Director

Stock Award

2026-03-31

111 shares · $23,292

MINOGUE MICHAEL R

Director

Buy

2026-02-25

2,030 shares · $499,847

KAPPLES JOHN W.

General Counsel

Stock Award

2026-02-24

1,885 shares

BENJAMIN ERIC

Chief Operating Officer

Stock Award

2026-02-24

3,822 shares

MCEVOY ASHLEY

Chief Executive Officer

Stock Award

2026-02-24

10,046 shares

BUDDEN LAUREN

Officer

Stock Award

2026-02-24

611 shares

PEASE FLAVIA H.

Chief Financial Officer

Stock Award

2026-02-24

3,822 shares

SINGH PREM

Officer

Stock Award

2026-02-24

2,140 shares

COUSIN LAETITIA

Officer

Stock Award

2026-02-24

1,044 shares

DAVIS LISA BLAIR

Officer

Stock Award

2026-02-24

2,140 shares

KAPPLES JOHN W.

General Counsel

Stock Award

2026-02-12

5,246 shares

BENJAMIN ERIC

Chief Operating Officer

Stock Award

2026-02-12

7,236 shares

BUDDEN LAUREN

Officer

Stock Award

2026-02-12

1,808 shares

SINGH PREM

Officer

Stock Award

2026-02-12

2,532 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A

2026-04-06

PODD filed a definitive proxy statement on April 6, 2026, providing shareholders with necessary information and voting materials for the upcoming annual meeting.

8-K

2026-03-12

Insulet Corporation (PODD) likely filed this 8-K to announce its fourth-quarter and full-year financial results.

8-K

2026-03-04

Insulet Corporation (PODD) filed an 8-K likely to announce its fourth quarter and full-year 2025 financial results.

8-K/A

2026-02-24

Insulet Corporation (PODD) filed an amendment to a previously submitted current report on February 24, 2026.

10-K

2026-02-18

PODD specializes in the development and sale of the Omnipod tubeless insulin delivery platform, specifically the Omnipod 5 and DASH systems. While specific financial metrics were not provided in the excerpts, the company's operations rely on integration with third-party continuous glucose monitors from Dexcom and Abbott. Identified risk areas include general operational uncertainties and cybersecurity.

8-K

2026-02-18

Insulet Corporation (PODD) filed an 8-K on February 18, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

2026-02-03

Insulet Corporation (PODD) filed an 8-K on February 3, 2026, likely to announce its fourth quarter and full-year financial results.

8-K

2025-12-19

8-K

2025-12-17

10-Q

2025-11-06

8-K

2025-11-06

8-K

2025-10-23

8-K

2025-09-16

8-K

2025-08-07

10-Q

2025-08-07

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

23 analysts

Truist Securities

2026-04-15

Maintains

Buy Buy

Goldman Sachs

2026-04-09

Maintains

Buy Buy

Citigroup

2026-04-07

down

Buy Neutral

Citigroup

2026-03-11

Maintains

Buy Buy

Citigroup

2026-02-19

Maintains

Buy Buy

Truist Securities

2026-02-19

Maintains

Buy Buy

Goldman Sachs

2026-02-19

Maintains

Buy Buy

Bernstein

2026-02-19

Maintains

Outperform Outperform

Oppenheimer

2026-02-19

Maintains

Outperform Outperform

JP Morgan

2026-02-19

Maintains

Overweight Overweight

Past News Coverage

Recent headlines mentioning PODD from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PODD

PODD Insulet Corporation - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!